Reliability and Validity of the Turkish Version of General Sleep Disturbance Scale (GSDS-T) in Multiple Sclerosis
Launched by ISTANBUL MEDENIYET UNIVERSITY · Mar 9, 2025
Trial Information
Current as of April 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a tool called the General Sleep Disturbance Scale (GSDS-T) which helps to measure sleep problems in people with Multiple Sclerosis (MS). The researchers want to see if this Turkish version of the scale is reliable and valid, meaning it accurately measures sleep disturbances for Turkish-speaking MS patients. This is important because while the scale has been tested in other patient groups, it hasn’t been specifically tested in those with MS yet.
To be eligible for this study, participants must be at least 18 years old, have been diagnosed with MS for at least two years, and have a specific level of disability (measured by something called the EDSS score) greater than 2. They should not have insomnia or severe symptoms that affect their ability to participate. Participants can expect to fill out questionnaires about their sleep habits and may contribute to important research that could help improve understanding of sleep issues in MS. The study is currently not recruiting participants, but it aims to gather valuable information that can lead to better sleep assessments for those living with this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Individuals over the age of 18 who have been diagnosed with Multiple Sclerosis for at least two years,
- • Those with an EDSS score \>2.
- • Those without symptoms of insomnia according to the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) diagnostic criteria
- • Individuals whose native language is Turkish and who have the ability to speak and understand.
- Exclusion Criteria:
- • Those with severe spasticity,
- • Those with vision and hearing problems,
- • Those with a known mental illness (major depression, schizophrenia, psychosis, etc.),
- • Those in an acute relapse phase,
- • Those using dietary supplements,
- • Those using tranquilizers or immunosuppressants.
About Istanbul Medeniyet University
Istanbul Medeniyet University is a prominent academic institution based in Turkey, dedicated to advancing medical research and education. As a clinical trial sponsor, the university leverages its extensive resources and expertise to conduct innovative studies aimed at improving healthcare outcomes. With a strong emphasis on ethical standards and scientific rigor, Istanbul Medeniyet University collaborates with healthcare professionals and researchers to explore new therapeutic strategies and contribute to the global body of medical knowledge. Their commitment to fostering a research-driven environment facilitates the development of cutting-edge treatments and enhances patient care within the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Maltepe, İstanbul, Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported